BioCentury | Oct 20, 2014
Company News

Xagenic management update

...chairman Hired: Timothy Still as president, CEO and a director, formerly president and CEO of Accumetrics Inc....
BioCentury | Sep 12, 2011
Clinical News

VerifyNow P2Y12 assay regulatory update

...based on platelet reactivity assay results may be considered, but is not advised as routine. Accumetrics'...
...with high residual platelet reactivity on antiplatelet therapy at risk for cardiovascular events. In August, Accumetrics...
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix. Accumetrics Inc....
BioCentury | Sep 5, 2011
Clinical News

VerifyNow P2Y12 assay: Pivotal trial additional data

...residual platelet reactivity with the VerifyNow P2Y12 assay at 12-24 hours and 30 days post-PCI. Accumetrics...
...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix. Accumetrics Inc....
BioCentury | May 23, 2011
Clinical News

VerifyNow P2Y12 assay regulatory update

...month. A 510(k) application for the assay for the indication is currently under FDA review. Accumetrics Inc....
BioCentury | Dec 6, 2010
Clinical News

VerifyNow P2Y12 assay: Pivotal trial data

...pivotal GRAVITAS trial in 2,214 evaluable patients with high residual platelet reactivity as measured by Accumetrics'...
...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix. Accumetrics Inc....
BioCentury | Sep 6, 2010
Financial News

Accumetrics financial update

...Permanente Ventures participated. The company raised $17 million in a first close in October 2009. Accumetrics Inc....
BioCentury | Oct 12, 2009
Financial News

Accumetrics completes venture financing

Accumetrics Inc. , San Diego, Calif. Business: Pharmacogenetics Date completed: 10/6/09 Type: Venture financing Raised: $16.5 million Investors: Arnerich Massena; BBT Fund/Apothecary Capital; Essex Woodlands Health Ventures; Kaiser Permanente Ventures; RiverVest Venture Partners Note: The capital...
BioCentury | Oct 7, 2009
Financial News

Accumetrics raises $16.5M

...Diagnostic company Accumetrics Inc. (San Diego, Calif.) raised $16.5 million in a venture round led by existing...
...will by funded in one transaction this year and in a second transaction in 2010. Accumetrics...
BioCentury | Nov 17, 2008
Company News

Accumetrics management update

Accumetrics Inc. , San Diego, Calif. Business: Pharmacogenetics Hired: John Young as CMO, while remaining a professor of medicine and director of the cardiovascular innovations program at the Ohio State University WIR Staff Cardiovascular...
BioCentury | Oct 27, 2008
Finance

Ebb & Flow

...Diagnostics companies, which represent only a handful of its portfolio companies, include diagnostic assay company Accumetrics...
Items per page:
1 - 10 of 15
BioCentury | Oct 20, 2014
Company News

Xagenic management update

...chairman Hired: Timothy Still as president, CEO and a director, formerly president and CEO of Accumetrics Inc....
BioCentury | Sep 12, 2011
Clinical News

VerifyNow P2Y12 assay regulatory update

...based on platelet reactivity assay results may be considered, but is not advised as routine. Accumetrics'...
...with high residual platelet reactivity on antiplatelet therapy at risk for cardiovascular events. In August, Accumetrics...
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix. Accumetrics Inc....
BioCentury | Sep 5, 2011
Clinical News

VerifyNow P2Y12 assay: Pivotal trial additional data

...residual platelet reactivity with the VerifyNow P2Y12 assay at 12-24 hours and 30 days post-PCI. Accumetrics...
...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix. Accumetrics Inc....
BioCentury | May 23, 2011
Clinical News

VerifyNow P2Y12 assay regulatory update

...month. A 510(k) application for the assay for the indication is currently under FDA review. Accumetrics Inc....
BioCentury | Dec 6, 2010
Clinical News

VerifyNow P2Y12 assay: Pivotal trial data

...pivotal GRAVITAS trial in 2,214 evaluable patients with high residual platelet reactivity as measured by Accumetrics'...
...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix. Accumetrics Inc....
BioCentury | Sep 6, 2010
Financial News

Accumetrics financial update

...Permanente Ventures participated. The company raised $17 million in a first close in October 2009. Accumetrics Inc....
BioCentury | Oct 12, 2009
Financial News

Accumetrics completes venture financing

Accumetrics Inc. , San Diego, Calif. Business: Pharmacogenetics Date completed: 10/6/09 Type: Venture financing Raised: $16.5 million Investors: Arnerich Massena; BBT Fund/Apothecary Capital; Essex Woodlands Health Ventures; Kaiser Permanente Ventures; RiverVest Venture Partners Note: The capital...
BioCentury | Oct 7, 2009
Financial News

Accumetrics raises $16.5M

...Diagnostic company Accumetrics Inc. (San Diego, Calif.) raised $16.5 million in a venture round led by existing...
...will by funded in one transaction this year and in a second transaction in 2010. Accumetrics...
BioCentury | Nov 17, 2008
Company News

Accumetrics management update

Accumetrics Inc. , San Diego, Calif. Business: Pharmacogenetics Hired: John Young as CMO, while remaining a professor of medicine and director of the cardiovascular innovations program at the Ohio State University WIR Staff Cardiovascular...
BioCentury | Oct 27, 2008
Finance

Ebb & Flow

...Diagnostics companies, which represent only a handful of its portfolio companies, include diagnostic assay company Accumetrics...
Items per page:
1 - 10 of 15